Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

A Study of TAK-994 in Adults With Narcolepsy

Phase 2

Terminated

Conditions: Narcolepsy Type 1 (NT 1)

Interventions: Drug: TAK-994
Drug: Placebo

First Posted Date: 2021-03-29

Last Posted Date: 2023-12-26

Lead Sponsor: Takeda

Target Recruit Count: 26

Registration Number: NCT04820842

Locations: 🇺🇸
Raleigh Neurology Associates,300209729, Raleigh, North Carolina, United States
🇺🇸
Fort Wayne Neurological Center 150711262, Fort Wayne, Indiana, United States
🇫🇮
Turku University Hospital, Turku, Finland

and more 67 locations

A Study of CDPATH™ to Help Manage and Treat Crohn's Disease

Phase 4

Active, not recruiting

Conditions: Crohn's Disease

Interventions: Other: CDPATH™
Other: Blood Draw

First Posted Date: 2021-03-22

Last Posted Date: 2024-07-24

Lead Sponsor: Takeda

Target Recruit Count: 200

Registration Number: NCT04809363

Locations: 🇺🇸
Grand Teton Research Group, PLL, Idaho Falls, Idaho, United States
🇺🇸
UMASS Memorial Medical Center, Worcester, Massachusetts, United States
🇺🇸
Gastro Center of Maryland, Columbia, Maryland, United States

and more 39 locations

Survey of Cabozantinib Used To Treat People With Renal Cell Carcinoma

Completed

Conditions: Renal Cell Carcinoma

Interventions: Drug: Cabozantinib

First Posted Date: 2021-03-18

Last Posted Date: 2024-04-24

Lead Sponsor: Takeda

Target Recruit Count: 388

Registration Number: NCT04804813

Locations: 🇯🇵
Takeda Selected Site, Tokyo, Japan

A Study of Vedolizumab in People With Ulcerative Colitis and Crohn's Disease

Phase 4

Completed

Conditions: Ulcerative Colitis
Crohn Disease

Interventions: Drug: Vedolizumab IV

First Posted Date: 2021-03-18

Last Posted Date: 2024-03-27

Lead Sponsor: Takeda

Target Recruit Count: 150

Registration Number: NCT04804540

Locations: 🇮🇳
Banglore Medical College & Research Institute, Bangalore, Karnatka, India
🇮🇳
Deccan College of Medical Sciences, Hyderabad, India
🇮🇳
Asian Institute of Gastroenterology, Hyderabad, Telangana, India

and more 14 locations

A Study of Kynteles Injection (Vedolizumab) in Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease or Chronic Pouchitis

Recruiting

Conditions: Crohn Disease
Inflammatory Bowel Diseases
Colitis, Ulcerative

First Posted Date: 2021-03-16

Last Posted Date: 2024-04-02

Lead Sponsor: Takeda

Target Recruit Count: 600

Registration Number: NCT04799496

Locations: 🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of
🇰🇷
Soon Chunhyang University Hospital Bucheon, Bucheon, Korea, Republic of
🇰🇷
Inje University Haeundae Paik Hospital, Busan, Korea, Republic of

and more 40 locations

A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

Phase 3

Recruiting

Conditions: Crohn's Disease (CD)

Interventions: Drug: Vedolizumab IV

First Posted Date: 2021-03-03

Last Posted Date: 2024-04-12

Lead Sponsor: Takeda

Target Recruit Count: 120

Registration Number: NCT04779320

Locations: 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
🇺🇸
I.H.S Health LLC, Kissimmee, Florida, United States

and more 92 locations

A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)

Phase 3

Recruiting

Conditions: Colitis, Ulcerative

Interventions: Drug: Vedolizumab

First Posted Date: 2021-03-03

Last Posted Date: 2024-04-19

Lead Sponsor: Takeda

Target Recruit Count: 120

Registration Number: NCT04779307

Locations: 🇧🇪
UZ Antwerpen, Edegem, Antwerpen, Belgium
🇧🇪
Universitair Ziekenhuis Brussel - PIN, Jette, Brussels, Belgium
🇺🇸
Phoenix Childrens Hospital -1919 E Thompson Rd, Phoenix, Arizona, United States

and more 62 locations

A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)

Phase 1

Terminated

Conditions: Relapsed and/or Refractory Multiple Myeloma (RRMM)

Interventions: Drug: TAK-981
Drug: Mezagitamab
Drug: Daratumumab and Hyaluronidase-fihj

First Posted Date: 2021-03-01

Last Posted Date: 2024-10-02

Lead Sponsor: Takeda

Target Recruit Count: 27

Registration Number: NCT04776018

Locations: 🇺🇸
Mayo Clinic Arizona - PPDS, Scottsdale, Arizona, United States
🇺🇸
Mayo Clinic Jacksonville - PPDS, Jacksonville, Florida, United States
🇺🇸
Weill Cornell Medical Center, New York, New York, United States

and more 10 locations

A Study of Prucalopride For Functional Constipation in Children and Teenagers

Phase 3

Terminated

Conditions: Constipation

Interventions: Other: Placebo
Drug: Prucalopride

First Posted Date: 2021-02-18

Last Posted Date: 2024-06-06

Lead Sponsor: Takeda

Target Recruit Count: 175

Registration Number: NCT04759833

Locations: 🇺🇸
Pediatric & Adult Research Center, Kissimmee, Florida, United States
🇺🇸
The University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States

and more 38 locations

A Study of Vonoprazan in Adults With Helicobacter Pylori

Phase 1

Completed

Conditions: Helicobacter Pylori

Interventions: Drug: Clarithromycin
Drug: Amoxicillin
Drug: Bismuth potassium citrate
Drug: Vonoprazan
Drug: Esomeprazole

First Posted Date: 2021-02-15

Last Posted Date: 2023-08-31

Lead Sponsor: Takeda

Target Recruit Count: 44

Registration Number: NCT04753437

Locations: 🇨🇳
West China Hospital, Sichuan University, Phase I Unit, Chengdu, Sichuan, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy